---
title: "ADC Therapeutics Q2 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295700574.md"
description: "ADC Therapeutics (ADCT) is set to report Q2 earnings on August 13th before market open. Consensus estimates project an EPS of -$0.22, a 12% year-over-year improvement, and revenue of $18.9 million, up 0.3% annually. Historically, the company has missed EPS estimates 100% of the time over the last two years but met revenue expectations 50% of the time."
datetime: "2026-08-12T19:30:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295700574.md)
  - [en](https://longbridge.com/en/news/295700574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295700574.md)
generator: "portal-rs"
---

# ADC Therapeutics Q2 earnings preview

ADC Therapeutics (ADCT) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. The consensus EPS Estimate is -$0.22 (+12.0% Y/Y) and the consensus Revenue Estimate is $18.9M (+0.3% Y/Y). Over the last 2 years, ADCT has beaten EPS estimates 0% of the time and has beaten revenue estimates 50% of the time. More on A...

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADC Therapeutics highlights ZYNLONTA growth opportunity in corporate presentation](https://longbridge.com/en/news/298617019.md)
- [ADCT: ZYNLONTA's clinical advances and label expansion aim to drive U.S. revenue beyond $600M](https://longbridge.com/en/news/298687077.md)
- [ADCT: ZYNLONTA shows high response rates and regulatory momentum in DLBCL and lymphoma studies](https://longbridge.com/en/news/298749364.md)
- [IMNM: Filed NDA for varegacestat and innovative ADC pipeline signal strong oncology momentum](https://longbridge.com/en/news/298941431.md)
- [IDYA: Darovasertib NDA nears completion as pipeline expands with DLL3 ADC, PRMT5, and Roche collaborations](https://longbridge.com/en/news/298488281.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**